Cite

    D. Paul et al.. “THU0645 Impact of second-line therapy with abatacept versus other targeted dmards on the risk for infection-related hospitalizations and associated costs among ra patients in the united states.” Annals of the rheumatic diseases, vol. 77, n.d., pp. 517–518. http://access.bl.uk/ark:/81055/vdc_100144731678.0x00004e